Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Growth markets revenue increased by 44 YoY to Rs. 812 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The company uses iPS cells to develop treatments for diseases relating to the kidney
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Subscribe To Our Newsletter & Stay Updated